{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:34:21Z","timestamp":1772778861227,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Survival remains heterogeneous in locally advancednasopharyngeal carcinoma (NPC) despite immunotherapy, highlighting the need for explainable artificial intelligence (AI) for risk-adapted care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 249 patients with locally advanced NPC between 2018 and 2025. Patients were randomly split into a training cohort (70%) and a validation cohort (30%). A Cox\u2013XGBoost survival modeling framework was developed using routinely available clinical variables to generate individualized risk scores and classify patients into low- and high-risk groups. Model discrimination was assessed using time-dependent ROC analysis. SHAP (SHapley Additive exPlanations) was applied to provide transparent, feature-level and patient-level interpretations of predicted risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Univariable Cox regression identified age, tumor grade, and N stage as significant prognostic factors. In the training cohort, the XGBoost-derived risk score robustly separated low- and high-risk groups, with significantly prolonged survival in the low-risk group (P &amp;lt; 0.001). In the validation cohort, the AUCs for predicting 1-, 2-, and 3-year OS were 0.784, 0.765, and 0.725, respectively. SHAP analyses consistently highlighted age as the strongest driver of predicted risk, followed by N stage and tumor grade; older age and advanced nodal disease were associated with higher predicted mortality risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An interpretable XGBoost-based survival model built from routine clinical variables provides clinically meaningful risk stratification for locally advanced NPC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1775802","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:30:18Z","timestamp":1772775018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Interpretable AI for treatment decision-making in immunoradiotherapy of locally advanced nasopharyngeal carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Guili","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Oncology, First People\u2019s Hospital of Zigong, Zigong Medica Science Academy","place":["Zigong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Oncology, First People\u2019s Hospital of Zigong, Zigong Medica Science Academy","place":["Zigong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zifu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jianyang People\u2019s Hospital","place":["Jianyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yangjiang People\u2019s Hospital","place":["Yangjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Oncology, First People\u2019s Hospital of Zigong, Zigong Medica Science Academy","place":["Zigong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101979","article-title":"Unveiling familial aggregation of nasopharyngeal carcinoma: Insights from oral microbiome dysbiosis","volume":"6","author":"Liao","year":"2025","journal-title":"Cell Rep Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106980","article-title":"Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma","volume":"158","author":"Yuan","year":"2024","journal-title":"Oral Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01083-2","article-title":"Early stage and locally advanced nasopharyngeal carcinoma treatment from present to future: where are we and where are we going","volume":"24","author":"Juarez-Vignon Whaley","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102840","article-title":"Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma","volume":"131","author":"Cai","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04214-8","article-title":"Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era","volume":"149","author":"Wang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/s41598-025-86178-6","article-title":"Exploring the influence of age on the causes of death in advanced nasopharyngeal carcinoma patients undergoing chemoradiotherapy using machine learning methods","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/pro6.70003","article-title":"Deep learning with attention modules and residual transformations improves hepatocellular carcinoma (HCC) differentiation using multiphase CT","volume":"9","author":"Wang","year":"2025","journal-title":"Prec Radiat Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8436","DOI":"10.1038\/s41598-024-59249-3","article-title":"A machine learning approach for predicting radiation-induced hypothyroidism in patients with nasopharyngeal carcinoma undergoing tomotherapy","volume":"14","author":"Quan","year":"2024","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12957-025-03860-9","article-title":"Machine learning model for predicting recurrence following intensity-modulated radiation therapy in nasopharyngeal carcinoma","volume":"23","author":"Wang","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S521378","article-title":"Machine learning radiomics for predicting response to MR-guided radiotherapy in unresectable hepatocellular carcinoma: A multicenter cohort study","volume":"12","author":"Su","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03588-0","article-title":"Lasso-Cox interpretable model of AFP-negative hepatocellular carcinoma","volume":"27","author":"Li","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.22465","article-title":"Immunotherapy for nasopharyngeal carcinoma: the earlier the better","volume":"330","author":"Bossi","year":"2023","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s12885-025-14108-w","article-title":"Effect and safety of immunotherapy among elder patients (age\u2009\u2265\u200965) with recurrent or metastatic nasopharyngeal carcinoma","volume":"25","author":"Xie","year":"2025","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/CBM-210357","article-title":"Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma","volume":"37","author":"Lin","year":"2023","journal-title":"Cancer biomark"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41597-024-03890-0","article-title":"A multicenter dataset for lymph node clinical target volume delineation of nasopharyngeal carcinoma","volume":"11","author":"Luo","year":"2024","journal-title":"Sci Data"},{"key":"B24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41746-025-02281-y","article-title":"Artificial intelligence-based personalized treatment strategies for unresectable hepatocellular carcinoma: integrating HSP90\u03b1 for prognosis and survival prediction","volume":"9","author":"Su","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8984","DOI":"10.1038\/s41598-023-35795-0","article-title":"Machine learning explainability in nasopharyngeal cancer survival using LIME and SHAP","volume":"13","author":"Alabi","year":"2023","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12672-022-00606-x","article-title":"Integrated radiomics, dose-volume histogram criteria and clinical features for early prediction of saliva amount reduction after radiotherapy in nasopharyngeal cancer patients","volume":"13","author":"Zhou","year":"2022","journal-title":"Discov Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03992-0","article-title":"Construction and validation of a machine learning model to predict the risk of nasopharyngeal carcinoma using multimodal clinical data: a single-center, retrospective study","volume":"28","author":"Li","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/pro6.70001","article-title":"Consensus statement on the exploration of clinical translation and application of electron ultra-high dose rate FLASH radiotherapy","volume":"9","author":"Luo","year":"2025","journal-title":"Prec Radiat Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/pro6.70007","article-title":"The evolution of prophylactic neck irradiation in nasopharyngeal carcinoma: Changing concepts and irradiation ranges","volume":"9","author":"Liao","year":"2025","journal-title":"Prec Radiat Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e073800","DOI":"10.1136\/bmj-2022-073800","article-title":"Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study","volume":"381","author":"Clift","year":"2023","journal-title":"BMJ"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s12672-025-02914-4","article-title":"Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma","volume":"16","author":"Xu","year":"2025","journal-title":"Discov Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13014-024-02496-5","article-title":"Improving the performance of deep learning models in predicting and classifying gamma passing rates with discriminative features and a class balancing technique: a retrospective cohort study","volume":"19","author":"Song","year":"2024","journal-title":"Radiat Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1775802\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:30:19Z","timestamp":1772775019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1775802\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1775802"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1775802","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"article-number":"1775802"}}